Pharmacokinetics and Safety of Ravidasvir and Danoprevir/r in Healthy Volunteers China
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2017-01-13
- Last Posted Date
- 2018-06-29
- Lead Sponsor
- Ascletis Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 18
- Registration Number
- NCT03020134
Efficacy and Safety of Ravidasvir + Danoprevir/r 12-week Oral Therapy in Treatment-Naive Non Cirrhotic G1 CHC Taiwan
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2017-01-13
- Last Posted Date
- 2020-10-22
- Lead Sponsor
- Ascletis Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 38
- Registration Number
- NCT03020095
Efficacy and Safety of Danoprevir/r + PR 12-week Triple Therapy in Treatment-Naive, Non-Cirrhotic, G1 CHC China II
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2017-01-13
- Last Posted Date
- 2018-07-26
- Lead Sponsor
- Ascletis Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 70
- Registration Number
- NCT03020004
Safety, Tolerability and Pharmacokinetics of Danoprevir/r in Healthy Volunteers China
- First Posted Date
- 2017-01-13
- Last Posted Date
- 2017-01-13
- Lead Sponsor
- Ascletis Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 18
- Registration Number
- NCT03019991
© Copyright 2024. All Rights Reserved by MedPath